News
SRPT
16.78
0.00%
0.00
Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO
Simply Wall St · 10h ago
Sarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer
Simply Wall St · 2d ago
Unusually active option classes on open August 7th
TipRanks · 3d ago
Barclays Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
TipRanks · 3d ago
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
TipRanks · 3d ago
Sarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop
Simply Wall St · 3d ago
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX), Revolution Medicines (RVMD) and Sarepta Therapeutics (SRPT)
TipRanks · 4d ago
Cantor Fitzgerald Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)
TipRanks · 4d ago
Sarepta price target lowered to $35 from $37 at Oppenheimer
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Agilon Health (AGL), CVS Health (CVS) and Sarepta Therapeutics (SRPT)
TipRanks · 4d ago
Wedbush Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)
TipRanks · 4d ago
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)
TipRanks · 4d ago
Morgan Stanley Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)
TipRanks · 4d ago
Sarepta Therapeutics (SRPT) Receives a Hold from Piper Sandler
TipRanks · 4d ago
Analyst Reiterates Sell on Sarepta as Core Franchise Weakens and Pipeline Remains Uncertain; $5 Price Target Unchanged
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT)
TipRanks · 4d ago
Sarepta rises on quarterly double-line beat
Seeking Alpha · 4d ago
*Sarepta Therapeutics 2Q Loss $4.89M >SRPT
Dow Jones · 4d ago
*Sarepta Therapeutics 2Q Loss/Shr 5c >SRPT
Dow Jones · 4d ago
Press Release: Sarepta Therapeutics Announces -3-
Dow Jones · 4d ago
More
Webull provides a variety of real-time SRPT stock news. You can receive the latest news about Sarepta Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.